NCT00781274View on ClinicalTrials.gov

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Hepatitis C
Interventions
DRUG

MP-424

750 mg every 8 hours for 12 weeks

DRUG

Ribavirin

600 - 1000 mg/day based on body weight for 24 weeks

DRUG

Peginterferon Alfa-2b

1.5 mcg/kg/week for 24 weeks

Trial Locations (1)

Unknown

Toranomon Hospital, Kawasaki

Sponsors
All Listed Sponsors
collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY